174 related articles for article (PubMed ID: 24086701)
1. Therapeutic potential of the translation inhibitor silvestrol in hepatocellular cancer.
Kogure T; Kinghorn AD; Yan I; Bolon B; Lucas DM; Grever MR; Patel T
PLoS One; 2013; 8(9):e76136. PubMed ID: 24086701
[TBL] [Abstract][Full Text] [Related]
2. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
[TBL] [Abstract][Full Text] [Related]
3. Silvestrol, a potential anticancer rocaglate derivative from Aglaia foveolata, induces apoptosis in LNCaP cells through the mitochondrial/apoptosome pathway without activation of executioner caspase-3 or -7.
Kim S; Hwang BY; Su BN; Chai H; Mi Q; Kinghorn AD; Wild R; Swanson SM
Anticancer Res; 2007; 27(4B):2175-83. PubMed ID: 17695501
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib and triptolide as combination therapy for hepatocellular carcinoma.
Alsaied OA; Sangwan V; Banerjee S; Krosch TC; Chugh R; Saluja A; Vickers SM; Jensen EH
Surgery; 2014 Aug; 156(2):270-9. PubMed ID: 24953273
[TBL] [Abstract][Full Text] [Related]
5. Synergy with interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma proliferation.
Yan Y; Wang L; He J; Liu P; Lv X; Zhang Y; Xu X; Zhang L; Zhang Y
Biomed Pharmacother; 2017 Apr; 88():395-402. PubMed ID: 28122304
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effect of fisetin combined with sorafenib in human cervical cancer HeLa cells through activation of death receptor-5 mediated caspase-8/caspase-3 and the mitochondria-dependent apoptotic pathway.
Lin MT; Lin CL; Lin TY; Cheng CW; Yang SF; Lin CL; Wu CC; Hsieh YH; Tsai JP
Tumour Biol; 2016 May; 37(5):6987-96. PubMed ID: 26662956
[TBL] [Abstract][Full Text] [Related]
7. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
[TBL] [Abstract][Full Text] [Related]
8. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
9. Capsaicin enhances the antitumor activity of sorafenib in hepatocellular carcinoma cells and mouse xenograft tumors through increased ERK signaling.
Zhang SS; Ni YH; Zhao CR; Qiao Z; Yu HX; Wang LY; Sun JY; Du C; Zhang JH; Dong LY; Wang K; Gao JJ
Acta Pharmacol Sin; 2018 Mar; 39(3):438-448. PubMed ID: 29188798
[TBL] [Abstract][Full Text] [Related]
10. Amentoflavone Enhances the Therapeutic Efficacy of Sorafenib by Inhibiting Anti-apoptotic Potential and Potentiating Apoptosis in Hepatocellular Carcinoma
Tsai JJ; Hsu FT; Pan PJ; Chen CW; Kuo YC
Anticancer Res; 2018 Apr; 38(4):2119-2125. PubMed ID: 29599330
[TBL] [Abstract][Full Text] [Related]
11. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y
BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167
[TBL] [Abstract][Full Text] [Related]
12. Total alkaloids of Rubus aleaefolius Poir inhibit hepatocellular carcinoma growth in vivo and in vitro via activation of mitochondrial-dependent apoptosis.
Zhao J; Chen X; Lin W; Wu G; Zhuang Q; Zhong X; Hong Z; Peng J
Int J Oncol; 2013 Mar; 42(3):971-8. PubMed ID: 23338043
[TBL] [Abstract][Full Text] [Related]
13. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.
Chao TI; Tai WT; Hung MH; Tsai MH; Chen MH; Chang MJ; Shiau CW; Chen KF
Cancer Lett; 2016 Feb; 371(2):205-13. PubMed ID: 26679051
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human acid sphingomyelinase as an adjuvant to sorafenib treatment of experimental liver cancer.
Savić R; He X; Fiel I; Schuchman EH
PLoS One; 2013; 8(5):e65620. PubMed ID: 23724146
[TBL] [Abstract][Full Text] [Related]
15. 6-Methoxyethylamino-numonafide inhibits hepatocellular carcinoma xenograft growth as a single agent and in combination with sorafenib.
Liu Y; Lou G; Norton JT; Wang C; Kandela I; Tang S; Shank NI; Gupta P; Huang M; Avram MJ; Green R; Mazar A; Appella D; Chen Z; Huang S
FASEB J; 2017 Dec; 31(12):5453-5465. PubMed ID: 28821631
[TBL] [Abstract][Full Text] [Related]
16. Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells.
Cervello M; Bachvarov D; Lampiasi N; Cusimano A; Azzolina A; McCubrey JA; Montalto G
PLoS One; 2013; 8(6):e65569. PubMed ID: 23776502
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
[TBL] [Abstract][Full Text] [Related]
18. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
Wang H; Zhang C; Chi H; Meng Z
Int J Oncol; 2018 Jun; 52(6):2051-2060. PubMed ID: 29620259
[TBL] [Abstract][Full Text] [Related]
19. Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas.
Oblinger JL; Burns SS; Akhmametyeva EM; Huang J; Pan L; Ren Y; Shen R; Miles-Markley B; Moberly AC; Kinghorn AD; Welling DB; Chang LS
Neuro Oncol; 2016 Sep; 18(9):1265-77. PubMed ID: 26951381
[TBL] [Abstract][Full Text] [Related]
20. Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression.
Hsu C; Lin LI; Cheng YC; Feng ZR; Shao YY; Cheng AL; Ou DL
Clin Cancer Res; 2016 May; 22(10):2555-64. PubMed ID: 26603262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
